ENTREMED, INC. (NASDAQ:ENMD)
CAPS Rating:
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.
Recs
As others say, a gamble with huge upside. But the small molecule research is promising and acquisition was a nice move. Keep close eye on it with stops.